Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study

Schizophrenia Research

Volumn 137, Issue 1-3, 2012, Pages 58-65

  Fraguas, David ^a,b   Gonzalez Pinto, Ana ^c   Micó, Juan Antonio ^d   Reig, Santiago ^a   Parellada, Mara ^a   Martínez Cengotitabengoa, Mónica ^c   Castro Fornieles, Josefina ^e   Rapado Castro, Marta ^a   Baeza, Immaculada ^e   Janssen, Joost ^a   Desco, Manuel ^a,f   Leza, Juan Carlos ^g   Arango, Celso ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Mental Health Department   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITY OF CÁDIZ   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^g UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Bipolar disorder; Brain volumes; First episode psychosis; Glutathione; GSH; MRI; Oxidative stress; Schizophrenia

Indexed keywords

GLUTATHIONE;

ADOLESCENT; ARTICLE; BRAIN SIZE; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRONTAL LOBE; GLUTATHIONE BLOOD LEVEL; GRAY MATTER; HUMAN; LONGITUDINAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARIETAL LOBE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; TEMPORAL LOBE;

ADOLESCENT; ANALYSIS OF VARIANCE; BRAIN; CASE-CONTROL STUDIES; CHILD; FEMALE; GLUTATHIONE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PSYCHOTIC DISORDERS; REGRESSION ANALYSIS;

EID: 84860837940     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.01.040     Document Type: Article

References (71)

1. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., Ozyurt H., Savaş H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26(5):995-1005.
2. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67(2):146-154.
3. Andreasen N.C., Rajarethinam R., Cizadlo T., Arndt S., Swayze V.W., Flashman L.A., O'Leary D.S., Ehrhardt J.C., Yuh W.T. Automatic atlas-based volume estimation of human brain regions from MR images. J. Comput. Assist. Tomogr. 1996, 20(1):98-106.
4. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
5. Ansari M.A., Scheff S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J. Neuropathol. Exp. Neurol. 2010, 69(2):155-167.
6. Arango C., Moreno C., Martinez S., Parellada M., Desco M., Moreno D., Fraguas D., Gogtay N., James A., Rapoport J. Longitudinal brain changes in early-onset psychosis. Schizophr. Bull. 2008, 34(2):341-353.
7. Arango C., Rapado-Castro M., Reig S., Castro-Fornieles J., González-Pinto A., Otero S., Baeza I., Moreno C., Graell M., Janssen J., Parellada M., Moreno D., Bargalló N., Desco M. Progressive brain changes in children and adolescents with first-episode psychosis. Arch. Gen. Psychiatry 2012, 69(1):16-26.
8. Asami T., Bouix S., Whitford T.J., Shenton M.E., Salisbury D.F., McCarley R.W. Longitudinal loss of gray matter volume in patients with first-episode schizophrenia: DARTEL automated analysis and ROI validation. NeuroImage 2012, 59(2):986-996.
9. Ashburner J., Friston K. Multimodal image coregistration and partitioning-a unified framework. NeuroImage 1997, 6(3):209-217.
10. Ben Othmen L., Mechri A., Fendri C., Bost M., Chazot G., Gaha L., Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(1):155-159.
11. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 2011, 35(3):878-893.
12. Buchsbaum M.S., Shihabuddin L., Brickman A.M., Miozzo R., Prikryl R., Shaw R., Davis K. Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophr. Res. 2003, 64(1):53-62.
13. Buckman T.D., Kling A., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res. 1990, 31(1):1-14.
14. Cabungcal J.H., Preissmann D., Delseth C., Cuenod M., Do K.Q., Schenk F. Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia. Neurobiol. Dis. 2007, 26(3):634-645.
15. Castro-Fornieles J., Parellada M., Gonzalez-Pinto A., Moreno D., Graell M., Baeza I., Otero S., Soutullo C.A., Crespo-Facorro B., Ruiz-Sancho A., Desco M., Rojas-Corrales O., Patiño A., Carrasco-Marin E., Arango C. The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. Schizophr. Res. 2007, 91(1-3):226-237. CAFEPS group.
16. Crow T.J. Is schizophrenia the price that Homo sapiens pays for language. Schizophr. Res. 1997, 28(2-3):127-141.
17. Dean O.M., van den Buuse M., Bush A.I., Copolov D.L., Ng F., Dodd S., Berk M. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr. Med. Chem. 2009, 16(23):2965-2976.
18. Dean O., Bush A.I., Berk M., Copolov D.L., van den Buuse M. Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. Pharmacol. Biochem. Behav. 2010, 97(2):293-300.
19. Desco M., Pascau J., Reig S., Gispert J.D., Santos A., Benito B., Molina V., Garcia-Barreno P. Multimodality image quantification using the Talairach grid. Medical Imaging 2001 Image Processing 2001, 1385-1392. San Diego.
20. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr. Opin. Neurobiol. 2009, 19(2):220-230.
21. Eack S.M., Hogarty G.E., Cho R.Y., Prasad K.M., Greenwald D.P., Hogarty S.S., Keshavan M.S. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch. Gen. Psychiatry 2010, 67(7):674-682.
22. Evans D.R., Parikh V.V., Khan M.M., Coussons C., Buckley P.F., Mahadik S.P. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins. Leukot. Essent. Fatty Acids 2003, 69(6):393-399.
23. Feairheller D.L., Park J.Y., Sturgeon K.M., Williamson S.T., Diaz K.M., Veerabhadrappa P., Brown M.D. Racial differences in oxidative stress and inflammation: in vitro and in vivo. Clin. Transl. Sci. 2011, 4(1):32-37.
24. Fenton W.S., Hibbeln J., Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatry 2000, 47(1):8-21.
25. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 2011, 14(1):123-130.
26. Gogtay N. Cortical brain development in schizophrenia: insights from neuroimaging studies in childhood-onset schizophrenia. Schizophr. Bull. 2008, 34(1):30-36.
27. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch. Gen. Psychiatry 2003, 60(6):585-594.
28. Janssen J., Reig S., Parellada M., Moreno D., Graell M., Fraguas D., Zabala A., Garcia Vazquez V., Desco M., Arango C. Regional gray matter volume deficits in adolescents with first-episode psychosis. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47(11):1311-1320.
29. Kasai K., Shenton M.E., Salisbury D.F., Hirayasu Y., Onitsuka T., Spencer M.H., Yurgelun-Todd D.A., Kikinis R., Jolesz F.A., McCarley R.W. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 2003, 60(8):766-775.
30. Kates W.R., Warsofsky I.S., Patwardhan A., Abrams M.T., Liu A.M., Naidu S., Kaufmann W.E., Reiss A.L. Automated Talairach atlas-based parcellation and measurement of cerebral lobes in children. Psychiatry Res. 1999, 91(1):11-30.
31. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., Williamson D., Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36(7):980-988.
32. Koo M.S., Levitt J.J., Salisbury D.F., Nakamura M., Shenton M.E., McCarley R.W. A cross-sectional and longitudinal magnetic resonance imaging study of cingulate gyrus gray matter volume abnormalities in first-episode schizophrenia and first-episode affective psychosis. Arch. Gen. Psychiatry 2008, 65(7):746-760.
33. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Cereser K.M., Gomes F.A., Belmonte-de-Abreu P.S., Berk M., Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(7):1677-1681.
34. Lee M., Cho T., Jantaratnotai N., Wang Y.T., McGeer E., McGeer P.L. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J. 2010, 24(7):2533-2545.
35. Lepping P., Delieu J., Mellor R., Williams J.H., Hudson P.R., Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. J. Clin. Psychiatry 2011, 72(3):273-285.
36. Li G., Liu L., Hu H., Zhao Q., Xie F., Chen K., Liu S., Chen Y., Shi W., Yin D. Age-related carbonyl stress and erythrocyte membrane protein carbonylation. Clin. Hemorheol. Microcirc. 2010, 46(4):305-311.
37. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol. Psychiatry 1998, 43(9):674-679.
38. Mahadik S.P., Pillai A., Joshi S., Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry 2006, 18(2):119-131.
39. Mane A., Falcon C., Mateos J.J., Fernandez-Egea E., Horga G., Lomeña F., Bargalló N., Prats-Galino A., Bernardo M., Parellada E. Progressive gray matter changes in first episode schizophrenia: a 4-year longitudinal magnetic resonance study using VBM. Schizophr. Res. 2009, 114(1-3):136-143.
40. Micó J.A., Rojas-Corrales M.O., Gibert-Rahola J., Parellada M., Moreno D., Fraguas D., Graell M., Gil J., Irazusta J., Castro-Fornieles J., Soutullo C., Arango C., Otero S., Navarro A., Baeza I., Martínez-Cengotitabengoa M., González-Pinto A. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC. Psychiatry 2011, 11:26.
41. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
42. Mitelman S.A., Canfield E.L., Chu K.W., Brickman A.M., Shihabuddin L., Hazlett E.A., Buchsbaum M.S. Poor outcome in chronic schizophrenia is associated with progressive loss of volume of the putamen. Schizophr. Res. 2009, 113(2-3):241-245.
43. Ozyurt B., Ozyurt H., Akpolat N., Erdogan H., Sarsilmaz M. Oxidative stress in prefrontal cortex of rat exposed to MK-801 and protective effects of CAPE. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(4):832-838.
44. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci. Lett. 2010, 479(3):317-320.
45. Pajonk F.G., Wobrock T., Gruber O., Scherk H., Berner D., Kaizl I., Kierer A., Müller S., Oest M., Meyer T., Backens M., Schneider-Axmann T., Thornton A.E., Honer W.G., Falkai P. Hippocampal plasticity in response to exercise in schizophrenia. Arch. Gen. Psychiatry 2010, 67(2):133-143.
46. Papas A.M. Determinants of antioxidant status in humans. Lipids 1996, 31(Suppl):S77-S82.
47. Patwardhan A.J., Eliez S., Warsofsky I.S., Glover G.H., White C.D., Giedd J.N., Peterson B.S., Rojas D.C., Reiss A.L. Effects of image orientation on the comparability of pediatric brain volumes using three-dimensional MR data. J. Comput. Assist. Tomogr. 2001, 25(3):452-457.
48. Radonjic N.V., Knezevic I.D., Vilimanovich U., Kravic-Stevovic T., Marina L.V., Nikolic T., Todorović V., Bumbasirević V., Petronijević N.D. Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Neuropharmacology 2010, 58(4-5):739-745.
49. Rapoport J.L., Giedd J.N., Blumenthal J., Hamburger S., Jeffries N., Fernandez T., Nicolson R., Bedwell J., Lenane M., Zijdenbos A., Paus T., Evans A. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 1999, 56(7):649-654.
50. Reig S., Moreno C., Moreno D., Burdalo M., Janssen J., Parellada M., Zabala A., Desco M., Arango C. Progression of brain volume changes in adolescent-onset psychosis. Schizophr. Bull. 2009, 35(1):233-243.
51. Reig S., Sánchez-González J., Arango C., Castro J., González-Pinto A., Ortuño F., Crespo-Facorro B., Bargalló N., Desco M. Assessment of the increase in variability when combining volumetric data from different scanners. Hum. Brain Mapp. 2009, 30(2):355-368.
52. Reig S., Parellada M., Castro-Fornieles J., Janssen J., Moreno D., Baeza I., Bargalló N., González-Pinto A., Graell M., Ortuño F., Otero S., Arango C., Desco M. Multicenter study of brain volume abnormalities in children and adolescent-onset psychosis. Schizophr. Bull. 2011, 37(6):1270-1280.
53. Richie J.P., Abraham P., Leutzinger Y. Long-term stability of blood glutathione and cysteine in humans. Clin. Chem. 1996, 42(7):1100-1105.
54. Rijcken C.A., Monster T.B., Brouwers J.R., de Jong-van den Berg L.T. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses. J. Clin. Psychopharmacol. 2003, 23(6):657-659.
55. Rijsdijk F.V., van Haren N.E., Picchioni M.M., McDonald C., Toulopoulou T., Hulshoff Pol H.E., Kahn R.S., Murray R., Sham P.C. Brain MRI abnormalities in schizophrenia: same genes or same environment. Psychol. Med. 2005, 35(10):1399-1409.
56. Satler J. Assessment of Children Cognitive Applications 2001, Publisher Inc, San Diego. fourth ed.
57. Soutullo C. Traducción al Español de la Entrevista Diagnóstica: Kiddie-Schedule for Affective Disorders & Schizophrenia, Present & Lifetime Version (K-SADS-PL, 1996) http://wwwcunes/la-clinica/departamentos-yservicios-medicos/psiquiatria-y-psicologia-medica/mas-sobreel-departamento/unidades/psiquiatria-infantil-y-adolescente.
58. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 2006, 188:510-518.
59. Styner M., Lieberman J.A., McClure R.K., Weinberger D.R., Jones D.W., Gerig G. Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(13):4872-4877.
60. Sun D., Phillips L., Velakoulis D., Yung A., McGorry P.D., Wood S.J., van Erp T.G., Thompson P.M., Toga A.W., Cannon T.D., Pantelis C. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr. Res. 2009, 108(1-3):85-92.
61. Takahashi T., Wood S.J., Yung A.R., Soulsby B., McGorry P.D., Suzuki M., Kawasaki Y., Phillips L.J., Velakoulis D., Pantelis C. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch. Gen. Psychiatry 2009, 66(4):366-376.
62. Talairach J., Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain 1988, Thieme Medical, New York.
63. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C., Collins D.L., Evans A.C., Kahn R.S. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32(10):2057-2066.
64. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry 2008, 63(1):106-113.
65. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468(7321):203-212.
66. Velakoulis D., Wood S.J., Wong M.T.H., McGorry P.D., Yung A.R., Phillips L.J., Smith D., Brewer W.J., Proffitt T., Desmond P., Pantelis C. Hippocampal and amygdala volumes differ according to psychosis stage and diagnosis: an MRI study of chronic schizophrenia, first-episode psychosis and ultra-high risk subjects. Arch. Gen. Psychiatry 2006, 63(2):139-149.
67. Wang J.F., Shao L., Sun X., Young L.T. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009, 11(5):523-529.
68. Wood S.J., Yucel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann. Acad. Med. Singapore 2009, 38(5). 396-6.
69. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid. Redox. Signal 2011, 15(7):2011-2035.
70. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81(2-3):291-300.
71. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Wu G.Y., Cao L.Y., Kosten T.A., Kosten T.R. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 2007, 32(9):2020-2024.